[Atanvarno]

Ich zitiere mal direkt aus dem Urteil http://www.tas-cas.org/fileadmin/user_up...ternet.pdf

[...]is it reasonable to impose a test that excludes her from the female athletes category for the purposes of competition, when she exhibits, naturally, the characteristiscs most closely associated with male competitive advantage? The Panel need to be satisfied on a balance of probabilities that it is
[....]
Excluding athletes from competing at all on the basis of a natural genetic advantage, or conditioning their right to compete on undergoing medical invention which reduces their athletic performance, imposes a significant detriment on the athletes concerned and is therefore only valid if it is clearly established to be a necessary and proportionate means of achieving fair competition.
[...]
The hyperandrogenism regulations are based on an implicit assumption that hyperandrogenic females enjoy a significant performance adavantage over their non hyper androgenic peers, which outranks the influence of any other single genetic or biological factor, and which is of comparable significance (if not identical magnitude) to the performance advantage that males typically enjoy over females. That is, it is the degree of competitive advantage that is said to make for unfair competition and absence of a level playing field

Das ist der Knackpunkt. Ich muss mich da insoweit korrigieren, als dass der CAS für eine Sperre nicht  (wie ich an anderer Stelle geschrieben habe) verlangt, dass die Leistungen hyperandrogener Frauen denen von Männern entsprechen müssen, aber sie müssen so gut sein, dass keine normale Frau sie erreichen kann. Jeder geschickte Anwalt wird da argumentieren, dass Semenya eben nicht so weit überlegen ist, dass keine Frau dass jemals erreichen könnte (das ist ja der Grund, warum sie keine Weltrekordversuche unternimmt).

Weiter

It is not self evident that a female athlete with a level of testosterone above 10nmol/l would enjoy a competitive advantage of a male athlete, which performance advantage would be, in the order of 10-12% [...] rather than say 1% (a relatively marginal advantage) [....]

Nota bene - 1% ist für den CAS marginal - ich bezweifele, dass sie 1,78% plötzlich als den für nicht hyperandrogene Frauen unerreichbaren Leistungsvorteil sehen werden.

--edit

the panel notes that the performance advantage of 3% suggested by Dr Bermon is significantly smaller that the 10-12% difference between elite male and elite female atheltic performance [...] it does not place great weight on the 3% figure referred to by Dr. Bermon, however it does demonstrate that [...] the performance advantage [...] may be of a different order to the performance advantage that males enjoy over females.

Das war, als die Bermon-Studie noch nicht veröffentlicht war. Da hat er den Wert noch überschätzt und 3% angegeben (gefunden hat er für die 800m dann 1,78%) - und selbst diese 3% wären dem CAS nicht zwingend genug gewesen.